Gregorio Maranon University Hospital | Spain
Author Profile
Scopus
Google Scholar
EARLY ACADEMIC PURSUITS
Since 2017, I have been dedicated to advancing the field of pharmacogenetics, beginning as a research assistant and progressing through to postdoctoral researcher at the Pharmacogenetics Laboratory of the Gregorio Marañón General University Hospital. My journey started with foundational research roles and evolved into leadership positions within various pharmacogenomic studies.
PROFESSIONAL ENDEAVORS
Starting as a research assistant, I gradually transitioned to roles as a predoctoral and postdoctoral researcher, accumulating invaluable experience and expertise in pharmacogenetics. My work has been primarily focused on pharmacogenomic studies in diverse medical areas such as colorectal cancer, multiple sclerosis, psychiatry, and intestinal inflammatory diseases.
Throughout my career, I have actively contributed to 21 publications in pharmacogenomics, with a particular emphasis on colorectal cancer, multiple sclerosis, psychiatry, and intestinal inflammatory diseases. Of these publications, I served as the first author for 14, showcasing my significant contributions to the field. Notably, my doctoral thesis in 2020 centered on intestinal inflammatory disease, underscoring my commitment to advancing knowledge in this area.
IMPACT AND INFLUENCE
My contributions have not gone unnoticed, as evidenced by receiving the AEFA (Spanish Clinical Laboratory Association) award for quality and innovation in 2019. Additionally, my research has been recognized through presentations at 20 national and international conferences, including 5 oral communications. I have been honored with the best oral communication award at three conferences, highlighting the impact of my work.
ACADEMIC CITES
My research has contributed to the academic discourse, with citations in various publications, further validating the significance and influence of my work in pharmacogenetics awards and related fields.
LEGACY AND FUTURE CONTRIBUTIONS
As an active member of the Spanish Society of Pharmacogenetics awards and the Spanish Association of Human Genetics, I continue to contribute to the advancement and dissemination of knowledge in these critical areas of public health. My ongoing commitment to research and collaboration ensures that my contributions will continue to shape the future of pharmacogenetics.
NOTABLE PUBLICATIONS
Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children 2023(3)
Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease 2023(7)
Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort 2023(7)
Genotyping of UGT1A1*80 as an Alternative to UGT1A1*28 Genotyping in Spain 2022(5)
Pharmacogenetics to avoid adverse reactions in cardiology: Ready for implementation? 2021(4)